Late-stage oncology Position Aravive as a late clinical-stage oncology partner with a focus on metastasis and GAS6-AXL pathway targeting. Sales opportunities exist in partnerships or out-licensing discussions for late-stage assets or combination therapy collaborations (radiation, chemotherapy, immunotherapies, and vaccines) to expand potential indications and accelerate commercialization.

Strategic collaborations Leverage their technology platform of high-affinity decoy receptors to attract collaboration with biotech and pharma companies seeking targeted cancer therapies, biomarker-driven development, or companion diagnostics aligned with AXL signaling to enhance patient selection and treatment efficacy.

Key leadership Engage with senior leadership hires such as Chief Commercial Officer, Chief Medical Officer, and Chief Financial Officer to identify alignment points for strategic partnerships, co-development agreements, and potential licensing deals that capitalize on their pipeline and clinical milestones.

Clinical milestones Monitor Phase 3 AXLerate-OC trial updates and other clinical readouts to time outreach for potential co-development, risk-sharing, or milestone-driven collaborations, especially in indications related to platinum-resistant ovarian cancer and bevacizumab treatment-naïve subgroups.

Funding and scale Recognize recent private placement funding and modest company size as indicators of potential appetite for collaboration structures that require flexible financing, such as milestone-based upfronts, equity-backed partnerships, or sponsored research arrangements to advance the pipeline.